Cancer clinical trials in the region Île-de-France

732 currently recruiting clinical trials
Region Île-de-France

Phase 2 Breast cancer #NCT06330064 #2023-509632-26-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 2 Breast cancer #NCT06330064 #2023-509632-26-00
Required HER2 statuses
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 2 Liver and bile duct cancer #NCT06330064 #2023-509632-26-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required BCLC stage (Barcelona Clinic Liver Cancer)
B C
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 2 Breast cancer #NCT07371585 #2025-521805-41-00
Required HER2 statuses
HER2 Positive
Required HR statuses
HR Negative HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Hormone therapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy Antibody Drug Conjugates (ADC)
1 recruiting site
SOLTI Breast Cancer Research Group
Phase 2 Breast cancer #NCT07007559
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
4 recruiting sites
ALX Oncologie Inc
Phase 2 Sarcoma and GIST #NCT07192068 #2025-522169-31-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
UNICANCER
Phase 2 Head and neck cancer #NCT07192068 #2025-522169-31-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
UNICANCER
Phase 2 Endometrial cancer #NCT07192068 #2025-522169-31-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
UNICANCER
Phase 2 Colon cancer Rectal cancer #NCT07192068 #2025-522169-31-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
UNICANCER
Phase 2 Lung cancer #NCT07192068 #2025-522169-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
UNICANCER